WeeksNews

FDA to Pull Drug Avandia Off the Market

Last week the Food and Drug administration (FDA), announced it will pull the drug Avandia off the market due to the diabetes drug's cardiovascular threat to patients. A 2007 analysis conducted by the Cleveland Clinic, found that those with type 2 diabetes who took Avandia (rosiglitazone) had a 40 percent increase in heart attack risk. Starting Nov. 18, only certified doctors will be able to prescribe the drug, and only to patients who have been alerted to the risks, who have already taken the drug safely, and who have found that other medications did not control their diabetes.